BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31151983)

  • 1. A novel model of controlling PD-L1 expression in ALK
    Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
    Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
    Ferreira CR; Manohar V; Zhao S; Bangs CD; Cherry A; Azevedo RS; Lage LAPC; Pereira J; Zerbini MCN; Gratzinger D; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):10-16. PubMed ID: 31809310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
    Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
    Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
    Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
    Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
    Yamamoto R; Nishikori M; Tashima M; Sakai T; Ichinohe T; Takaori-Kondo A; Ohmori K; Uchiyama T
    Cancer Sci; 2009 Nov; 100(11):2093-100. PubMed ID: 19703193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
    Shen J; Li S; Medeiros LJ; Lin P; Wang SA; Tang G; Yin CC; You MJ; Khoury JD; Iyer SP; Miranda RN; Xu J
    Mod Pathol; 2020 Mar; 33(3):324-333. PubMed ID: 31383967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
    Rajan SS; Amin AD; Li L; Rolland DC; Li H; Kwon D; Kweh MF; Arumov A; Roberts ER; Yan A; Basrur V; Elenitoba-Johnson KSJ; Chen XS; Puvvada SD; Lussier YA; Bilbao D; Lim MS; Schatz JH
    Oncogene; 2020 Mar; 39(10):2103-2117. PubMed ID: 31804622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].
    Wang C; Chen X; Chen XY; You ZJ
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):598-603. PubMed ID: 34078046
    [No Abstract]   [Full Text] [Related]  

  • 9. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
    Prutsch N; He S; Berezovskaya A; Durbin AD; Dharia NV; Maher KA; Matthews JD; Hare L; Turner SD; Stegmaier K; Kenner L; Merkel O; Look AT; Abraham BJ; Zimmerman MW
    Cell Rep Med; 2024 Mar; 5(3):101472. PubMed ID: 38508140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.
    Ma L; Lv J; Dong Y; Zhang X; Li X; Zhang H; Nong J; Zhang Q; Qin N; Yang X; Wang J; Zhang S
    Interdiscip Sci; 2019 Jun; 11(2):266-272. PubMed ID: 31098955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Anand M; Lai R; Gelebart P
    Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
    Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
    Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
    Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
    Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.
    Spaccarotella E; Pellegrino E; Ferracin M; Ferreri C; Cuccuru G; Liu C; Iqbal J; Cantarella D; Taulli R; Provero P; Di Cunto F; Medico E; Negrini M; Chan WC; Inghirami G; Piva R
    Haematologica; 2014 Jan; 99(1):116-24. PubMed ID: 23975180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.